My Prostate Cancer Treatment

Oncotype DX Legal Information

The information presented on this site is intended to provide patients with newly diagnosed prostate cancer, as well as their friends and family, an opportunity to learn how the information provided by the Oncotype DX Genomic Prostate Score can be used, along with other clinical measures, to help patients and their doctors make treatment decisions. Patients should consult their doctor to determine the best treatment decision for their individual disease.

National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

Copyright © 2013-2019 Genomic Health, Inc. All rights reserved. Genomic Health, Oncotype, and Oncotype DX are trademarks, and Genomic Prostate Score is a pending registered trademark of Genomic Health Inc. MyProstateCancerTreatment.org is sponsored by Genomic Health, Inc., a clinical laboratory in Redwood City, California that developed and offers the Oncotype DX Prostate Cancer Assay. Genomic Health is responsible for the content of MyProstateCancerTreatment.org.